Proceedings of the International Symposium on Polymer Therapeutics - Recent Progress in Clinics and Future Prospects, held July 13-14, 2001, in Nara, Japan.

The technology of polymer science has developed considerably during the past half-century, and this volume describes some of the aspects of this technology that will have a great impact in the future. Among these advances, for example, are gene delivery to specific disease sites and carrier polymers that respond to a stimulus or particular environment. Cancer targeted drug delivery is another focused area of this volume because of the important nature of EPR-effect of polymer drugs in tumor. Included are discussions of as many examples as possible of polymer drugs that have achieved, or are close to clinical use. The concept of "Polymer drugs" here is limited to primarily injectable and water-soluble agents, although also covered are some drugs in micellar form or liposomes.

This book is intended for students and researchers in the field of pharmacology who have particular interests in drug delivery, targeting, and formulation, as well as for clinicians such as oncologists who are interested in the field. People who work at regulatory agencies should also be aware such that drugs with great potential are being developed and will be beneficial to many patients, as well as to health insurance agencies because of improved cost effectiveness.

Inhalt

Challenges in Polymer Therapeutics: State of the Art and Prospects of Polymer Drugs; A. Kabanov, T. Okano. Factors and Mechanism of 'EPR' Effect and the Enhanced Antitumor Effects of Macromolecular Drugs Including SMANCS; Jun Fang, T.Sawa, H. Maeda. PEG-Adenosine Deaminase and PEG-Asparaginase; F. Davis. Peginterferon alfa-2a (40KD): A Potent Long-Acting Form of Interferon alfa-2a for the Treatment of Hepatitis C; M. Modi, M. Lamb, M. Shiomi. PEG-Methioninase; R.Hoffman. Poly-(L)-Glutamic Acid-Paclitaxel (CT-2103)[XYOTAX®], a Biodegradable Polymeric Drug Conjugate: Characterization, Preclinical Pharmacology, and Preliminary Clinical Data; J. Singer, B. Baker, P. De Vries, A. Kumar, S. Shaffer, E. Vawter, M. Bolton, P. Garzone. HPMA Copolymer Delivery of Chemotherapy and Photodynamic Therapy in Ovarian Cancer; C.M. Peterson, Jane-Guo Shiah, Yongen Sun, P. Kopecková, T. Minko, R. Straight, J. Kopecek. Drug-HPMA-HuIg Conjugates Effective Against Human Solid Cancer; B. Ríhová, J. Strohalm, K. Kubácková, M. Jelínková, L. Rozprimová, M. Sírová, D. Plocová, T. Mrkvan, M. Kovár, J. Pokorná, T. Etrych, K. Ulbrich#. CM-Dextran-Polyalcohol-Camptothecin Conjugate: DE310 with a Novel Carrier System and its Preclinical Data; K. Inoue, E. Kumazawa, H. Kuga, H. Susaki, N. Masubuchi, T. Kajimura. Polymeric Micelle Drug Carrier Systems: PEG-PAsp(Dox) and Second Generation of Micellar Drugs; N. Nishiyama, K. Kataoka. An Interim Analysis of Phase I Clinical Trial of MCC-465, a Doxorubicin (DXR) Encapsulated in PEG-immunoliposome, in Patients with Metastatic Stomach Cancer; Y. Matsumura. Polymer Conjugates for Imaging; A. Perkins. S-Nitrosylated Polyethylene Glycol-conjugated Hemoglobin Derivative as a Candidate Material for Oxygen Therapeutics; K.Nakai, I. Sakuma, H. Togashi, M.Yoshioka, T. Sugawara, H. Satoh, A. Kitabatake. Index.